Clinical trials: Covid19 Vaccination
SARS-CoV Infection, COVID-19
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine.
- Conditions
- SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
- Trial name
- SARS (NCT04761822)
- Testing
- Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine
- Where
- 29 sites in United States
- Volunteers
- 746 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with…
- Trial name
- COVID-19 (NCT05374954)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated, COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- 10 sites in China
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Myocardial Injury, Vaccine Adverse Reaction
Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers
The aim of the study is to prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.
- Conditions
- Myocardial Injury, Vaccine Adverse Reaction, COVID-19
- Trial name
- NCT05308680
- Testing
- BNT162b2
- Where
- Israel
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
COVID-19, Trust
Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust - Study 1
The goal of this study is to assess how community-led group discussions about health-related topics may alter beliefs and intentions regarding healthcare recommendations, such as COVID-19 testing and vaccination.
- Trial name
- NCT06650462
- Testing
- Community-led discussion
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Old Dominion University
COVID 19, Influenza
Community-based Behavioral Intervention to Increase Vaccination Using MOST
The proposed study responds to the need for community-engaged interventions to increase vaccine uptake among populations experiencing health disparities.
- Trial name
- NCAP2 (NCT06614361)
- Testing
- Health education on COVID and flu vaccination, Nurse-led shared decision-making, Text messages
- Sponsor
- New York University
Covid19
Using Text Messages to Improve COVID-19 Vaccination Uptake
COVID-19 vaccinations significantly reduce the risk of getting seriously ill or dying from COVID-19. Since December 2020, the UK has rolled out vaccinations according to the Joint Committee for Vaccinations and Immunity (JCVI)…
- Trial name
- NCT04895683
- Testing
- Text message content
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Immunogenicity, Hematological Malignancies
Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies. At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy for the prevention of Covid-19.
- Conditions
- Immunogenicity, Hematological Malignancies, Covid-19, Vaccine Response Impaired
- Trial name
- NCT04878822
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi
Vaccination; Infection, COVID-19
Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine
COVID-19 vaccines are limited in supply, especially in low- and middle-income countries, leading to substantial morbidity and mortality.
- Trial name
- MILESTONE (NCT05315362)
- Testing
- solid microneedle skin patch, mRNA-1273, standard needle
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
COVID-19
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection.
- Trial name
- DAN-COVID (NCT07279766)
- Testing
- mRNA-1273 (Moderna COVID-19 vaccine)
- Where
- 2 sites in Denmark
- Volunteers
- 41,060 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
COVID19
Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
This study is a continuation study of the original V-01-I phase trial, using a single-center, single-arm, open design to evaluate the immunogenicity and safety of the third dose booster immunization of Recombinant SARS-CoV-2…
- Trial name
- NCT05050474
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205096
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Covid-19, Subjects Vaccinated Against Covid-19
Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations
Limited information is available regarding the effects of various factors that may influence the duration and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) vaccinations. This virus causes Covid-19.
- Trial name
- Covid-19-Abs (NCT04944095)
- Testing
- Change in SARS-CoV-2 Antibody Levels
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Dr. Sidney J. Stohs
Kidney Transplant Infection, SARS-CoV Infection
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)
None of the vaccines approved, or in clinical trials, have so far been tested on transplanted patients. If they produce an immune response to the Spike protein of SARS-CoV-2 it is unknown how long the protective immunity will…
- Trial name
- SCV-KTx-imm (NCT04747522)
- Testing
- SARS-CoV-2 vaccine
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- Oslo University Hospital
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS CoV 2 Infection, Vaccination Reaction
Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.
Since the beginning of 2020, a major pandemic due to the new emerging coronavirus (SARS-CoV-2) has been spreading around the world.
- Trial name
- VACCICOVID (NCT04934215)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
This is a multicenter, parallel groups, partially randomized, open-label, blank-controlled adaptive platform study to evaluate the effectiveness of a second COVID-19 vaccine booster in Chinese adults who are charactered as the…
- Trial name
- NCT05855408
- Testing
- Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose…
- Trial name
- MOSAIC (NCT04894435)
- Testing
- mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant]
- Where
- 8 sites in Canada
- Volunteers
- 669 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695117
- Testing
- IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
Immunity to COVID-19
Immunity After COVID-19 Vaccination
The purpose of the research is to evaluate new blood tests, which measure immunity to the COVID-19 coronavirus after vaccination. These tests will be used to measure T-cell and antibody immunity after COVID-19 vaccination.
- Trial name
- NCT04883164
- Testing
- Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Plexision
Health Care Utilization, Health Care Associated Infection
COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring
Primary objective: 1. Monitor adverse events (Adverse Event Following Immunization - AEFI) in vaccinated subjects and analyze the associations with: (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.)…
- Trial name
- SAPIENZAVAX (NCT04844632)
- Testing
- Vaccine anti-Covid19
- Where
- Italy
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza